Reviewnpj biomedical innovations2026
Progress and challenges in transplantation of human pluripotent stem cell derived cardiomyocytes for cardiac therapy.
Review in npj biomedical innovations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Oxygen-generating Microparticles Enhance Viability and Functionality of Human Pluripotent Stem Cell-derived Cardiomyocytes for Myocardial Infarction Therapy.Stem cell reviews and reports · 2026Article
- Cardiac regeneration and repair: the emerging mechanisms and therapeutic approaches.Molecular biomedicine · 2026Review
- Needle gauge and length effects on human stem cell viability during injection: a comprehensive review.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Myocardial infarction and heart failure remain leading causes of mortality worldwide. Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) represent a promising approach to regenerating damaged myocardium and restoring cardiac function. This review highlights advancements in hPSC-CM differentiation, scale-up, and clinical-grade manufacturing; delivery approaches; and insights from preclinical and clinical studies. We also examine mechanisms of repair, key challenges and mitigation strategies, and future directions to advance hPSC-CM therapies toward clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.